Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. ROSGQ.PINK

Rosetta Genomics Ltd (ROSGQ PINK) stock market data APIs

$0.0001 0(0%) as of July 26, 2024
Price chart is built with Anychart

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

Rosetta Genomics Ltd Financial Data Overview

0.0001
0.0001
-
0.0001
0.0001
0.0001-0.0001
29 648
5 930 K
2 859 K
0
19.99
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ROSGQ',
Type: 'Common Stock',
Name: 'Rosetta Genomics Ltd',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000HJC443',
ISIN: 'IL0011026494',
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: '2007-02-27',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Diagnostics & Research',
HomeCategory: NULL,
IsDelisted: false,
}

Rosetta Genomics Ltd Fundamental Data is available in our Financial Data APIs

  • Net Revenue 2 859 K
  • EBITDA -10 351 000
  • Earnings Per Share -0.27
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Rosetta Genomics Ltd Earnings via APIs

  • Latest Release 2024-05-16
  • EPS/Forecast 0

Get Rosetta Genomics Ltd End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
Do you have any questions?
support@eodhistoricaldata.com